|
2024
|
Invention
|
Treatment of multiple sclerosis and neuromyelitis optica.
The present disclosure provides for th... |
|
|
Invention
|
Treatment for skeletal diseases caused by intracellular protein trafficking defects.
The present... |
|
|
Invention
|
Multi-omic approach for assessing systemic lupus erythematosus heterogeneity in treatment respons... |
|
|
Invention
|
Compositions and methods for treating osteoarthritis using a cd14 inhibitor.
Disclosed herein ar... |
|
2023
|
Invention
|
Variant-specific exogenous dna template-free correction of pathogenic variants.
Provided herein ... |
|
|
Invention
|
Prox1 prevents myxomatous valve disease by inhibiting pdgf-b signaling.
The present invention in... |
|
|
Invention
|
Anti-vimentin antibodies are associated with higher severity of sjögren's syndrome. A method, ass... |
|
|
Invention
|
Preparation of anti-apc monoclonal antibody and use thereof. Provided in the present invention is... |
|
|
Invention
|
Fully human monoclonal antibodies that broadly neutralize sars-cov-2.
The present invention incl... |
|
|
Invention
|
N-acetylcysteine attenuates aortic stenosis progression by inhibiting shear-mediated tgf-beta act... |
|
|
Invention
|
Autoantibody biomarkers of ro/ss-a antibody negative sjogren's syndrome/sjogren's disease. The pr... |
|
|
Invention
|
Protein biomarkers of inflammatory activity in multiple sclerosis. The present invention includes... |
|
2022
|
Invention
|
Human streptococcus pneumoniae antibodies and uses therefor.
The present invention is directed t... |
|
|
Invention
|
Microbiome transplantation for osteoarthritis therapy.
The present invention includes compositio... |
|
|
Invention
|
Biomarkers for systemic lupus erythematosus disease, and intensity and flare.
The present invent... |
|
|
Invention
|
Biomarkers and methods for measuring and monitoring inflammatory disease activity.
Biomarkers us... |
|
|
Invention
|
Okn-007 as an agent to improve longevity. The present invention includes compositions and methods... |
|
|
Invention
|
Okn-007 as a therapeutic agent for neurodegenerative diseases. The present invention includes com... |
|
2021
|
Invention
|
Compositions and methods for microbial disease treatment. The present disclosure provides compoun... |
|
|
Invention
|
Peripheral blood dna methylation models as predictors of knee osteoarthritis radiographic progres... |
|
|
Invention
|
Compositions and methods for preventing the interaction between sars-cov-2 and l-sign.
The prese... |
|
|
Invention
|
Inhibition of endothelial ets family transcription factors promotes flow-dependent ocular vessel ... |
|
|
Invention
|
Biomarkers for a systemic lupus erythematosus (sle) disease activity immune index that characteri... |
|
|
Invention
|
Monoclonal antibody for human activated protein c, and preparation method therefor and use thereo... |
|
|
Invention
|
Monoclonal antibody against human activated protein c and preparation and use thereof. The presen... |
|
|
Invention
|
Method for determining whether a systemic lupus erythematosus (sle) patient is undergoing a pre-f... |
|
|
Invention
|
Biomarkers for identifying relapses in multiple sclerosis.
The present invention includes a meth... |
|
|
Invention
|
Biomarkers for identifying relapses in multiple sclerosis. The present invention includes a metho... |
|
|
Invention
|
Antibody tests for identifying ro negative sjogren's syndrome and use as biomarkers for dysregula... |
|
|
Invention
|
Antibody tests for identifying ro negative sjögren's syndrome and use as biomarkers for dysregula... |
|
2020
|
Invention
|
Okn-007 as a therapeutic agent.
The present invention includes compositions and methods for trea... |
|
|
Invention
|
Okn-007 as a therapeutic agent. The present invention includes compositions and methods for treat... |
|
|
Invention
|
Method of transporting an agent across blood-brain, blood-cochlear or blood-cerebrospinal fluid b... |
|
|
Invention
|
Nachr-alpha7 agonists and nachr-alpha7 antagonists for treating ulcerative colitis (uc) and crohn... |
|
|
Invention
|
Soluble mediators for predicting systemic lupus erythematosus activity events.
Systemic Lupus Er... |
|
|
Invention
|
Soluble mediators for predicting systemic lupus erythematosus activity events. Systemic Lupus Ery... |
|
|
Invention
|
Antibodies to polyphosphate decrease fibrosis. Polyphosphate activates the intrinsic pathway of c... |
|
|
Invention
|
Compositions and methods for treating sjogren's syndrome. The present invention provides composit... |
|
2019
|
Invention
|
Monoclonal antibodies to eltd1 and uses thereof.
The present disclosure is directed to novel mon... |
|
|
Invention
|
Treatment for age- and oxidative stress-associated muscle atrophy and weakness.
The present inve... |
|
2008
|
G/S
|
publications, namely, magazines, brochures, booklets, and teaching materials, in the field of med... |
|
1988
|
G/S
|
[ SCIENTIFIC REAGENTS ] [ PHARMACEUTICALS, namely, ANTIBIOTICS AND CHEMOTHERAPEUTIC AGENTS FOR TR... |
